FDA user fee reauthorization legislation being reconciled between House and Senate will not include track-and-trace standards, according to several sources.
A last-minute proposal using ideas both industry and FDA supported appears not to have been able to resolve concerns, forcing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?